ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer.
|
31193124 |
2019 |
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP.
|
30537410 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin.
|
31653698 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer.
|
30572097 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin.
|
31685298 |
2019 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer.
|
30572097 |
2019 |
Malignant neoplasm of ovary
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP.
|
30537410 |
2019 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin.
|
31653698 |
2019 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer.
|
31193124 |
2019 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin.
|
31685298 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway.
|
29486472 |
2018 |
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Nucleus and/or cytoplasma of β-catenin expression might be associated with tumor progression and could be a possible potential predictive factor of poor prognosis in OC patients.
|
30103006 |
2018 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway.
|
29486472 |
2018 |
Malignant neoplasm of ovary
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Nucleus and/or cytoplasma of β-catenin expression might be associated with tumor progression and could be a possible potential predictive factor of poor prognosis in OC patients.
|
30103006 |
2018 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer.
|
28090074 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process.
|
28650464 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer.
|
28440436 |
2017 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer.
|
28090074 |
2017 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer.
|
28440436 |
2017 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process.
|
28650464 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our study identifies activated Wnt signalling to be a marker for precursor lesions of OC and successfully develops a mouse model that mimics the earliest events in pathogenesis of OC by constitutively activating βcatenin.
|
27588493 |
2016 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.
|
26341496 |
2016 |
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.
|
26455321 |
2016 |
Malignant neoplasm of ovary
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Importantly, JRK expression was aberrantly elevated in 21% of colorectal cancers, 15% of breast and ovarian cancers and was associated with increased expression of β-catenin target genes and increased cell proliferation.
|
26455321 |
2016 |
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.
|
26341496 |
2016 |